November 2, 2026
Upcoming Live Webinar: Advancing mRNA Synthesis with AvantCap® Q1 and PrimeCap™ T7 RNA PolymeraseFollowing the joint technical note published with Takara Bio earlier this September, ExploRNA Therapeutics is thrilled to announce a new collaborative live webinar diving deeper into our optimized mRNA synthesis workflow. Join us on Thursday, November 12, 2026, at...
Read more
October 21, 2026
ExploRNA Therapeutics Heading to AMM ASCENT 2026 in Coronado!ExploRNA Therapeutics is heading to California next week for AMM ASCENT 2026 (October 28–30 | Coronado Island Marriott Resort & Spa), organized by the Alliance for mRNA Medicines. Piotr Stępniak, our VP of Business Development, will be on-site to...
Read more
October 1, 2026
Eurostars Project CAPSULIX: mRNA and LNPs for engineered cell therapyEurostars Granted Project “A novel generation of mRNA and lipid nanoparticles for engineered cell therapy applications” – CAPSULIX (10471) October 1st, 2026 Eurostars, a European joint programme that is part of the European Partnership on Innovative SMEs,...
Read more
September 29, 2026
ExploRNA Therapeutics and Wacker Biotech are strengthening R&D partnershipExploRNA Therapeutics and Wacker Biotech are strengthening our existing R&D partnership to better serve developers in the field of nucleic acid technologies and RNA/LNP-based applications. Recognizing our complementary strengths, we have established a collaborative framework designed to facilitate seamless...
Read more
September 22, 2026
ExploRNA Therapeutics and Łukasiewicz – IChP Announce Strategic Partnership to Advance GMP Manufacturing of Next-Generation mRNA Cap AnalogsWARSAW, Poland – September 22, 2026 – ExploRNA Therapeutics, a pioneering biotechnology company specializing in novel mRNA capping technologies, and the Łukasiewicz Research Network – Industrial Chemistry Institute (Łukasiewicz – IChP) today announced a strategic partnership. The collaboration focuses...
Read more
September 14, 2026
ExploRNA and Takara Bio Release Technical Note Demonstrating High-Yield, Low-dsRNA mRNA Synthesis WorkflowExploRNA Therapeutics, in collaboration with Takara Bio, has published a comprehensive technical note detailing an optimized co-transcriptional mRNA synthesis workflow that combines ExploRNA’s tetranucleotide Cap1 analog, AvantCap® Q1, with Takara Bio’s engineered PrimeCap™ T7 RNA Polymerase. Achieving efficient, clinical-grade...
Read more
July 28, 2026
ExploRNA Therapeutics Announces Distribution Agreement with AS ONE Corporation in JapanExploRNA Therapeutics today announced that AS ONE Corporation has been appointed as one of its distributors in Japan. Under the agreement, AS ONE will offer ExploRNA’s cap analog products, including ExploCap, AvantCap AG, AvantCap Q1 and AvantCap Q2, to...
Read more
July 23, 2026
ExploRNA Therapeutics presents new mRNA insights and research at EUROBIOTECH 2026ExploRNA Therapeutics was proud to take part in the 10th Central European Congress of Life Sciences (EUROBIOTECH 2026) in Kraków, Poland. As a hub for regional and global life science breakthroughs, the congress provided an ideal stage to showcase...
Read more
May 30, 2026
ExploRNA at BIO 2026 in San DiegoWe are thrilled for the upcoming Biotechnology Innovation Organization Convention in San Diego. Our Board Member Tomasz Piec, and BD Director Piotr Stępniak are looking forward to meeting with partners from around the world and discussing how ExploRNA’s technology...
Read more
April 25, 2026
ExploRNA Therapeutics to Attend ASGCT 2026 in BostonExploRNA Therapeutics is pleased to announce that our Director of Business Development, Piotr Stępniak, will be attending the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in Boston, taking place May 11–15, 2026. As a leading event...
Read more